Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1952 - A cross-trial comparison of pemetrexed-platinum followed by pemetrexed continuation maintenance versus gemcitabine-cisplatin without maintenance in chemotherapy-naive patients with advanced nonsquamous non-small-cell lung cancer


08 Oct 2016


Poster Display


Yi-Long Wu


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


Y. Wu1, B. Zhang2, X. Wang2, M. Orlando3, H. Chi2

Author affiliations

  • 1 Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, 510080 - Guangzhou/CN
  • 2 Oncology, Lilly China Drug Development and Medical Affairs Center, Shanghai/CN
  • 3 Oncology, Eli Lilly Interamerica Inc, Buenos Aires/AR


Abstract 1952


This cross-trial pooled analysis aimed to demonstrate improved efficacy of pemetrexed (pem) - platinum (plat) followed by pem continuation maintenance over gemcitabine (gem)-cisplatin (cis) without maintenance in advanced nonsquamous non-small-cell lung cancer (NSQ NSCLC) patients.


Analysis populations consisted of patients with similar baseline characteristics selected from 3 trials (JMDB, PARAMOUNT, and JMII) using a propensity score method. JMDB investigated first-line pem-cis (pem 500 mg/m2 + cis 75 mg/m2 every 21 days [q21d] for 6 cycles) and gem-cis (gem 1250 mg/m2 on days 1, 8 + cis 75 mg/m2 day 1 q21d for 6 cycles). PARAMOUNT compared pem maintenance vs placebo after patients with NSQ NSCLC completed 4 cycles of first-line pem-cis without progressive disease (PD). JMII examined pem-carboplatin (carb) (pem 500 mg/m2 + carb area under the curve 6 mg/mL*min q21d for 4 cycles) induction therapy followed by pem maintenance in NSQ NSCLC patients. Kaplan-Meier method and Cox regression were used to analyze overall survival (OS) and progression-free survival (PFS). Statistical inference was conducted on the overall population (OP); the analysis on the maintenance eligible population (MEP [completed 4 cycles without PD]) was descriptive.


OP was created with 530 patients in pem-plat and 534 patients in gem-cis arms. Of these, 287 in pem-plat and 285 in gem-cis were the MEP. In the OP, significant improvement were observed in pem-plat group than gem-cis, both in PFS (hazard ratio [HR] = 0.87, 95% confidence interval (CI): 0.77-0.99, p = .029; median PFS 5.16 m vs 5.49 m) and in OS (HR = 0.79, 95% CI: 0.69-0.91, p = .001; median OS 12.29 m vs 10.91 m). For the MEP, both median PFS (7.39 m vs 6.64 m) and median OS (18.37 m vs 13.63 m) were prolonged in pem-plat compared with gem-cis.


This cross-trial analysis supports pem-plat induction followed by pem continuation maintenance therapy as a preferred choice over gem-cis without maintenance as first-line chemotherapy for patients with advanced NSQ NSCLC.

Clinical trial identification

1. JMDB: NCT00087711 (Last verified: May 2009). 2. PARAMOUNT: NCT00789373 (Last verified: March 2016). 3. JMII: NCT01020786 (Last verified: June 2013)

Legal entity responsible for the study

Eli Lilly and company


Eli Lilly and company


Y-L. Wu: Ongoing unpaid consultant with Eli Lilly and MSD, and has received speaker fee from Eli Lilly, Roche, Boehringer Ingelheim, and AstraZeneca. B. Zhang, X. Wang: Currently employee of Eli Lilly and Company. M. Orlando, H. Chi: Employee and shareholders of Eli Lilly and Company.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings